Record Details

Elevated level of interleukin-6 before radiofrequency ablation of pulmonary vein increases the risk of relapse after six months in patients with paroxysmal atrial fibrillation

Translational Medicine

View Archive Info
 
 
Field Value
 
Title Elevated level of interleukin-6 before radiofrequency ablation of pulmonary vein increases the risk of relapse after six months in patients with paroxysmal atrial fibrillation
Повышение уровня интерлейкина-6 перед радиочастотной аблацией легочных вен увеличивает риск рецидива через шесть месяцев у пациентов с пароксизмальной фибрилляцией предсердий
 
Creator Oksana Karnialiuk M.; Scientific and Practical center of Cardiology
Оксана Корнелюк Михайловна; Республиканский научно-практический центр «Кардиология»
 
Subject фибрилляция предсердий; радиочастотная аблация; интерлейкин-6; пороговое значение; atrial fibrillation; radiofrequency ablation; interleukin - 6; threshold
 
Description The level of IL-6 more than 1.77 mmol / L before the radiofrequency ablation of pulmonary veins increases the risk of recurrence after six months in patients with paroxysmal atrial fibrillation.
Уровень интерлейкина-6 до радиочастотной аблации легочный вен более 1,77 мкмоль/л увеличивает риск рецидива через шесть месяцев у пациентов с пароксизмальной фибрилляцией предсердий.
 
Publisher Federal Almazov North-West Medical Research Centre, Saint Petersburg, Russia
 
Date 2016-12-23
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
—
 
Format application/pdf
 
Identifier http://transmed.almazovcentre.ru/jour/article/view/191
 
Source Translational Medicine; Том 3, № 3 (2016); 67-72
Трансляционная медицина; Том 3, № 3 (2016); 67-72
2410-5155
2311-4495
 
Language rus
 
Relation http://transmed.almazovcentre.ru/jour/article/view/191/192
Kobza R., Hindricks G., Tanner H., Schirdewahn P., Dorszewski A., Piorkowski C., Gerds-Li J.H., Kottkamp H. Late recurrent arrhythmias after ablation of atrial fibrillation: incidence, mechanisms, and treatment. Heart Rhythm. 2004;1(6): 676-683.
Nilsson B., Chen X., Pehrson S., Kөber L., Hilden J., Svendsen J.H. Recurrence of pulmonary vein conduction and atrial fibrillation after pulmonary vein isolation for atrial fibrillation: a randomized trial of the ostial versus the extraostial ablation strategy. Am Heart J. 2006; 152(3): 537. e1-8.
Rostock T., Rotter M., Sanders P., Takahashi Y., Jaïs P., Hocini M., Hsu L.F., Sacher F., Clémenty J., Haïssaguerre M. High-density activation mapping of fractionated electrograms in the atria of patients with paroxysmal atrial fibrillation. Heart Rhythm. 2006;3(1): 27-34.
Pokushalov E., Romanov A., De Melis M., Artyomenko S., Baranova V., Losik D., Bairamova S., Karaskov A., Mittal S., Steinberg JS. Progression of atrial fibrillation after a failed initial ablation procedure in patients with paroxysmal atrial fibrillation: a randomized comparison of drug therapy versus reablation. Circ Arrhythm Electrophysiol. 2013; 6(4): 754-760.
Camm A.J., Lip G.Y., De Caterina R., Savelieva I., Atar D., Hohnloser S.H., Hindricks G., Kirchhof P.; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21): 2719-2147.
Calkins H., et al. Heart Rhythm Society Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm. 2012; 9(4): 632-696.e21.
Kaitani K., et al, EAST-AF Trial Investigators. Efficacy of Antiarrhythmic Drugs Short-Term Use After Catheter Ablation for Atrial Fibrillation (EAST-AF) trial. Eur Heart J. 2016;37(7): 610-618.
Hatzinikolaou-Kotsakou E., Tziakas D., Hotidis A., Stakos D., Floros D., Papanas N., Chalikias G., Maltezos E., Hatseras D.I. Relation of C-reactive protein to the first onset and the recurrence rate in lone atrial fibrillation. Am J Cardiol. 2006;97(5): 659-661.
den Uijl D.W., Delgado V., Tops L.F., Ng A.C., Boersma E., Trines S.A., Zeppenfeld K., Schalij M.J., van der Laarse A., Bax J.J. Natriuretic peptide levels predict recurrence of atrial fibrillation after radiofrequency catheter ablation. Am Heart J. 2011;161(1): 197-203.
Rossi A., Enriquez-Sarano M., Burnett J.C. Jr., Lerman A., Abel M.D., Seward J.B. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol. 2000;35(5): 1256-1262.
Hijazi Z., Oldgren J., Siegbahn A., Granger C.B., Wallentin L. Biomarkers in atrial fibrillation: a clinical review. Eur Heart J. 2013;34(20): 1475-1480.
Leftheriotis D.I., Fountoulaki K.T., Flevari P.G., Parissis J.T., Panou F.K., Andreadou I.T., Venetsanou K.S., Iliodromitis E.K., Kremastinos D.T. The predictive value of inflammatory and oxidative markers following the successful cardioversion of persistent lone atrial fibrillation. Int J Cardiol. 2009;135(3): 361-369.
Henningsen K.M., Therkelsen S.K., Bruunsgaard H., Krabbe K.S., Pedersen B.K., Svendsen J.H. Prognostic impact of hs-CRP and IL-6 in patients with persistent atrial fibrillation treated with electrical cardioversion. Scand J Clin Lab Invest. 2009;69(3): 425-432.
Henningsen K.M., Nilsson B., Bruunsgaard H., Chen X., Pedersen B.K., Svendsen J.H. Prognostic impact of hs-CRP and IL-6 in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Scand Cardiovasc J. 2009;43(5): 285-291.
Liu T., Li G., Li L., Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a metaanalysis. J Am Coll Cardiol. 2007;49(15): 1642-1648.
 
Rights Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Авторы, публикующие в данном журнале, соглашаются со следующим:Авторы сохраняют за собой авторские права на работу и предоставляют журналу право первой публикации работы на условиях лицензии Creative Commons Attribution License, которая позволяет другим распространять данную работу с обязательным сохранением ссылок на авторов оригинальной работы и оригинальную публикацию в этом журнале.Авторы сохраняют право заключать отдельные контрактные договорённости, касающиеся не-эксклюзивного распространения версии работы в опубликованном здесь виде (например, размещение ее в институтском хранилище, публикацию в книге), со ссылкой на ее оригинальную публикацию в этом журнале.Авторы имеют право размещать их работу в сети Интернет (например в институтском хранилище или персональном сайте) до и во время процесса рассмотрения ее данным журналом, так как это может привести к продуктивному обсуждению и большему количеству ссылок на данную работу (См. The Effect of Open Access).